JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AbbVie Inc

Suletud

SektorTervishoid

198.07 -0.35

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

198

Max

198.64

Põhinäitajad

By Trading Economics

Sissetulek

1.3B

1.3B

Müük

2.1B

15B

P/E

Sektori keskmine

92.578

34.393

Aktsiakasum

2.97

Dividenditootlus

3.31

Kasumimarginaal

9.66

Töötajad

55,000

EBITDA

-4.3B

117M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.3% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.31%

2.54%

Järgmine tulemuste avaldamine

29. okt 2025

Järgmine dividendimakse kuupäev

15. aug 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. okt 2025

Turustatistika

By TradingEconomics

Turukapital

12B

348B

Eelmine avamishind

198.42

Eelmine sulgemishind

198.07

Uudiste sentiment

By Acuity

22%

78%

40 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

AbbVie Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. juuli 2025, 12:46 UTC

Tulu

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30. juuni 2025, 13:02 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25. apr 2025, 13:57 UTC

Tulu

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25. apr 2025, 12:52 UTC

Tulu

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31. juuli 2025, 12:08 UTC

Tulu

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31. juuli 2025, 11:46 UTC

Tulu

AbbVie Raises FY Outlook

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q Adj EPS $2.97 >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q EPS 52c >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q Rev $15.42B >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31. juuli 2025, 11:44 UTC

Tulu

AbbVie 2Q Net $938M >ABBV

30. juuni 2025, 12:47 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30. juuni 2025, 12:33 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30. juuni 2025, 12:33 UTC

Omandamised, ülevõtmised, äriostud

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30. juuni 2025, 12:32 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30. juuni 2025, 12:31 UTC

Omandamised, ülevõtmised, äriostud

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7. mai 2025, 09:30 UTC

Peamised uudised

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28. apr 2025, 12:44 UTC

Tulu

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28. apr 2025, 09:33 UTC

Tulu

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. apr 2025, 16:03 UTC

Tulu

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25. apr 2025, 14:00 UTC

Peamised uudised
Tulu

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. apr 2025, 12:24 UTC

Peamised uudised
Tulu

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. apr 2025, 12:03 UTC

Peamised uudised
Tulu

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25. apr 2025, 11:43 UTC

Tulu

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

9.3% tõus

12 kuu keskmine prognoos

Keskmine 216.47 USD  9.3%

Kõrge 255 USD

Madal 170 USD

Põhineb 17 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

11

Osta

6

Hoia

0

Müü

Tehniline skoor

By Trading Central

180.37 / 195.54Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

40 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.